

Media release

Zug, 19 June 2023

Shareholders' Meeting of HBM Healthcare Investments approved all proposals by the Board of Directors

At today's ordinary Shareholders' Meeting of HBM Healthcare Investments Ltd the shareholders approved all proposals submitted by the Board of Directors. A total of about 32% of all shares were represented at the Shareholders' Meeting.

The Chairman of the Board of Directors Hans Peter Hasler and the existing board members Dr Rudolf Lanz, Mario G. Giuliani, Dr Stella X. Xu and Dr Elaine V. Jones were re-elected for a further one year term. The existing members of the Compensation Committee Mario G. Giuliani, Dr Stella X. Xu and Dr Elaine E. Jones were also re-elected for a further one year term. Furthermore, the shareholders approved the proposed compensation to the Board of Directors and to the Management.

Further, the Shareholders' Meeting approved a par value repayment of CHF 7.50 per share. The cash payment will be made on 7 August 2023. The registered shares with entitlement to the distribution will be traded for the last time on 2 August 2023 (from 3 August 2023 without, ex-date).

Further, the Shareholders approved the amendments of the articles of association according to the motion of the Board of Directors.

Contact

For further information, please contact Dr Andreas Wicki,
Phone: +41 41 710 75 77, andreas.wicki@hbmhealthcare.com

HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

HBM Healthcare Investments Ltd

Bundesplatz 1, CH-6300 Zug | Phone: +41 41 710 75 77 | info@hbmhealthcare.com | www.hbmhealthcare.com
Follow us on Twitter: [@HbmHealthcare](https://twitter.com/HbmHealthcare)

Disclaimer

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to U.S. persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments Ltd's securities were not issued in accordance with the U.S. securities laws, and may not be sold, offered for sale, or delivered in the USA or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions.